<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297283</url>
  </required_header>
  <id_info>
    <org_study_id>Leadless ECG Evaluation Study</org_study_id>
    <nct_id>NCT01297283</nct_id>
  </id_info>
  <brief_title>Leadless Electrocardiogram (ECG) Evaluation Study</brief_title>
  <acronym>LECG</acronym>
  <official_title>Leadless ECG Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The leadless electrocardiogram (LECG) is a new technology incorporated into the Consulta
      CRT-P to obtain an ECG signal from the Consulta CRT-P similar to a surface ECG obtained from
      the device programmer (PECG) or an external ECG machine.

      The purpose of the study is to obtain more data on leadless ECG to determine whether LECG
      during standard CRT follow-up can indeed adequately replace surface ECG and to evaluate if
      it can be used during remote follow-up evaluations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The leadless electrocardiogram (LECG) is a new technology incorporated into the Consulta
      CRT-P to obtain an ECG signal from the Consulta CRT-P similar to a surface ECG obtained from
      the device programmer (PECG) or an external ECG machine. The LECG signals are measured from
      three electrodes mounted on the outside of the pacemaker housing and provides an electrical
      far field signal of the electrical activity of the heart. The LECG provides three ECG
      channels as different projections of the electrical activity of the heart, similar to the
      surface ECG. Clinical interest of LECG is threefold. First, ECG recordings are routinely
      used to perform pacemaker and cardiac resynchronization systems in-office follow-up mainly
      to determine pacing thresholds. Connection of ECG electrodes to the patient as well as the
      time needed to acquire an acceptable ECG signal during routine follow-up could be saved
      using LECG which would make follow-up easier and less time consuming. Secondly, connecting
      ECG electrodes requires the patient to be present at the clinic for the follow-up. Use of
      LECG in conjunction with a transmitting system will allow remote patient follow-up. In that
      case, correct ventricular capture confirmation by the LECG is of key importance. Finally,
      LECG stored in device memory at the time of an arrhythmia episode occurrence, can help
      better classify it.

      The following factors might influence the quality of the LECG and/or the axis of the LECG:

        -  temporal changes of the electrode tissue interface due to device pocket healing process

        -  changes in device position and orientation over time

        -  body motion

        -  poor LECG contact due to oversized device pocket with replacement procedure. The
           purpose of this study is to obtain more data on leadless ECG (LECG) to determine
           whether LECG during standard CRT follow-up can indeed adequately replace surface ECG
           and to evaluate if it can be used during remote follow-up evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Proportion of Patients With LECG Performing Clinically Equivalent to PECG During Standard Pacemaker Follow-up Procedure.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>During CRT-P standard follow-up, ECG is used to determine atrial, left and right ventricular pacing thresholds. As primary endpoint, we will consider the proportion of patients for which for all leads LECG provides pacing threshold values that are clinically equivalent to those obtained with PECG taken as reference. The analysis will be performed on data collected at the 1-Month Follow-Up visit when the device pocket healing process is completed. Clinical equivalence will be defined as the LECG threshold values being no more than 0.5 volts different from the PECG threshold values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Possibility to Determine Ventricle Capture by an Independent Reviewer.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigator will simulate loss of capture (LOC) at 1-Month Follow-Up visit by printing strips of LOC in both ventricular leads, LOC in LV lead only, LOC in RV lead only, no LOC. One strip randomly selected among them by the study manager will be submitted to an independent reviewer. With help of the PHD template LECG strips (intrinsic, RV paced, LV paced, BiV paced) of this patient, he/she will determine which lead is capturing.
The endpoint is the proportion of correct classifications of ventricular capture done by then independent reviewer of LECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Stability of LECG Performance Over Time.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two parameters will be used to evaluate LECG changes between PHD and 1-Month on the same LECG vector: intrinsic R wave amplitude and P waves visibility (selection the LECG vector at PHD with best combination of the highest R wave and most visible P wave).
R wave amplitude measurements as well as P wave visibility assessment will be done by the independent reviewer.
The endpoints evaluated are:
mean R wave changes from PHD to 1-month
proportion of patients with stable P wave visibility at PHD and 1-Month (meaning both visits visible or both visits not visible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of LECG in New Devices Versus Device Replacements.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The two following parameters will be used to compare the quality of LECG in new implants versus device replacements at PHD and 1-Month on the same LECG vector:
Intrinsic R wave amplitude
P waves visibility The LECG vector at PHD with best combination of the highest R wave and most visible P wave will be selected.
R wave amplitude measurements as well as P wave visibility assessment will be done by the independent reviewer.
The endpoints will be:
comparison of mean R wave values at PHD and 1-month
comparison of proportion of patients with P wave visible at PHD and 1-month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Posture Changes and Artifact-inducing Maneuvers on the LECG Quality.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The intrinsic R wave amplitude and P waves visibility will be taken to evaluate the effect of posture changes and artifact-inducing maneuvers on the quality of LECG at the 1-Month Follow-Up visit (LECG vector with best combination of the highest R wave and most visible P wave).
The endpoints will be R wave amplitude and P wave visibility in different positions (meaning visible or not visible in both positions).
R wave changes and proportion of patients with stable P waves visibility at lying position versus other positions will be calculated by an independent reviewer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Factors Such as Device Rotation, Device Fixation, Device Side Facing the Skin, Position of Lead Loops in the Pocket, Use of Antiseptic Solution, Skin Type, Body Mass Index on the Quality of Leadless ECG.</measure>
    <time_frame>30 to 120 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following factors will be evaluated to investigate whether they influence the LECG quality:
device position (subcutaneous, submuscular, etc)
device rotation
device fixation
device side facing the skin
position of lead loops in the pocket
use of antibiotics in the pocket
skin type (loose, normal, firm)
body mass index (BMI)
The endpoints will be:
describe R wave amplitude values
describe proportion of patients with P wave visible on intrinsic LECG strips recorded at 1-Month FU.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Leadless ECG first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Programmer ECG first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurements of pacing thresholds are done first with the support of the programmer ECG</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LECG first</intervention_name>
    <description>Measurement of the pacing threshold with the support of a leadless ECG</description>
    <arm_group_label>Leadless ECG first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Programmer ECG first</intervention_name>
    <description>Pacing threshold measurements are done with the support of the programmer ECG</description>
    <arm_group_label>Programmer ECG first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a CRT-P indication and

          -  patient who has signed an informed consent form.

        Exclusion Criteria:

          -  patient younger than 18 years and/or

          -  unable to complete the 1-Month Follow-up visit and/or

          -  legally incompetent or illiterate and therefore unable to provide an informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françoise HIDDEN-LUCET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital La Pitié Salpêtrière, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2011</firstreceived_date>
  <firstreceived_results_date>December 23, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Cardiac resynchronization</keyword>
  <keyword>Leadless ECG</keyword>
  <keyword>Follow-up</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>200 patients were enrolledand were followed for at least 1 month in 25 institutions in France (max 50 patients per center). The first patient was enrolled on 16th of September 2010. The last patient was enrolled on the 13th of September 2011. The last follow-up visit took place on 5th of December 2011.</recruitment_details>
      <pre_assignment_details>The point of enrollment was defined as the time before device implant at which a patient has signed and dated the Informed Consent Form. At that point, the patient needed to be followed for the duration of the study (until the 1-Month Follow-Up visit) unless a Study Exit Form was completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Subjects</title>
          <description>Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Subjects</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="195"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="77.6" spread="9.83"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="80" lower_limit="74" upper_limit="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="145"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>BMC Index</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25.64" spread="4.38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilogramms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="72.9" spread="14.37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilogramms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="71" lower_limit="63" upper_limit="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.68" spread="0.09"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.69" lower_limit="1.62" upper_limit="1.75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>BMC Index</title>
          <units>kg/m²</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.75" lower_limit="22.64" upper_limit="27.76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Class I</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Class II</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Class III</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Class IV</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not available</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31.67" spread="8.18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>LVEF</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31" lower_limit="25" upper_limit="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>General cardiovascular history</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Cardiomyopathy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="187"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Congenital Heart Disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Congestive Heart Failure</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Coronary artery disease</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hypertension</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Myocardial infarction</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Pulmonary hypertension (PH)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Valve dysfunction</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other cardiovascular history</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cardiovascular Surgical History</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>NONE</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ablation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Coronary artery bypass graft (CABG)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Coronary artery intervention</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Valve surgery</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other cardiovascular surgery</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Previous Device</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>CRT-D implant</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>CRT-P implant</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>ICD implant</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>IPG implant</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Atrial Arrhythmia History</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>NONE</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Atrial fibrillation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Atrial flutter</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Atrial tachycardia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Premature atrial complexes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sinus node dysfunction</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Supraventricular tachycardia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other atrial arrhythmias</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ventricular Arrhythmia History</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>NONE</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="174"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Premature ventricular complexes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Torsades de pointes</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ventricular asystole</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ventricular flutter</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ventricular tachycardia, non-sustained</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ventricular tachycardia, sustained monomorphic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ventricular tachycardia, sustained, unknown morpho</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other ventricular arrhythmias</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>AV Junctional Arrhythmia History</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>NONE</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1st degree AV block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2nd degree AV block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>3rd degree AV block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Intermediate bundle branch block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Left bundle branch block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Right bundle branch block</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other AV junctional arrhythmias and blocks</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With LECG Performing Clinically Equivalent to PECG During Standard Pacemaker Follow-up Procedure.</title>
        <description>During CRT-P standard follow-up, ECG is used to determine atrial, left and right ventricular pacing thresholds. As primary endpoint, we will consider the proportion of patients for which for all leads LECG provides pacing threshold values that are clinically equivalent to those obtained with PECG taken as reference. The analysis will be performed on data collected at the 1-Month Follow-Up visit when the device pocket healing process is completed. Clinical equivalence will be defined as the LECG threshold values being no more than 0.5 volts different from the PECG threshold values.</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Overall Subjects</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients With LECG Performing Clinically Equivalent to PECG During Standard Pacemaker Follow-up Procedure.</title>
            <description>During CRT-P standard follow-up, ECG is used to determine atrial, left and right ventricular pacing thresholds. As primary endpoint, we will consider the proportion of patients for which for all leads LECG provides pacing threshold values that are clinically equivalent to those obtained with PECG taken as reference. The analysis will be performed on data collected at the 1-Month Follow-Up visit when the device pocket healing process is completed. Clinical equivalence will be defined as the LECG threshold values being no more than 0.5 volts different from the PECG threshold values.</description>
            <units>proportion</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Atrial lead</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99" spread="0.41" lower_limit="0.95" upper_limit="1.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RV Lead</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.98" spread="0.56" lower_limit="0.95" upper_limit="1.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LV Lead</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.98" spread="1.19" lower_limit="0.95" upper_limit="1.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>All leads</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.96" lower_limit="0.92" upper_limit="0.98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Possibility to Determine Ventricle Capture by an Independent Reviewer.</title>
        <description>The investigator will simulate loss of capture (LOC) at 1-Month Follow-Up visit by printing strips of LOC in both ventricular leads, LOC in LV lead only, LOC in RV lead only, no LOC. One strip randomly selected among them by the study manager will be submitted to an independent reviewer. With help of the PHD template LECG strips (intrinsic, RV paced, LV paced, BiV paced) of this patient, he/she will determine which lead is capturing.
The endpoint is the proportion of correct classifications of ventricular capture done by then independent reviewer of LECG.</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Proportion of Patients Correctly Classified</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Subjects</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluation of the Possibility to Determine Ventricle Capture by an Independent Reviewer.</title>
            <description>The investigator will simulate loss of capture (LOC) at 1-Month Follow-Up visit by printing strips of LOC in both ventricular leads, LOC in LV lead only, LOC in RV lead only, no LOC. One strip randomly selected among them by the study manager will be submitted to an independent reviewer. With help of the PHD template LECG strips (intrinsic, RV paced, LV paced, BiV paced) of this patient, he/she will determine which lead is capturing.
The endpoint is the proportion of correct classifications of ventricular capture done by then independent reviewer of LECG.</description>
            <units>proportion</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.51" lower_limit="0.43" upper_limit="0.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Stability of LECG Performance Over Time.</title>
        <description>Two parameters will be used to evaluate LECG changes between PHD and 1-Month on the same LECG vector: intrinsic R wave amplitude and P waves visibility (selection the LECG vector at PHD with best combination of the highest R wave and most visible P wave).
R wave amplitude measurements as well as P wave visibility assessment will be done by the independent reviewer.
The endpoints evaluated are:
mean R wave changes from PHD to 1-month
proportion of patients with stable P wave visibility at PHD and 1-Month (meaning both visits visible or both visits not visible).</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of LECG in New Devices Versus Device Replacements.</title>
        <description>The two following parameters will be used to compare the quality of LECG in new implants versus device replacements at PHD and 1-Month on the same LECG vector:
Intrinsic R wave amplitude
P waves visibility The LECG vector at PHD with best combination of the highest R wave and most visible P wave will be selected.
R wave amplitude measurements as well as P wave visibility assessment will be done by the independent reviewer.
The endpoints will be:
comparison of mean R wave values at PHD and 1-month
comparison of proportion of patients with P wave visible at PHD and 1-month.</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Posture Changes and Artifact-inducing Maneuvers on the LECG Quality.</title>
        <description>The intrinsic R wave amplitude and P waves visibility will be taken to evaluate the effect of posture changes and artifact-inducing maneuvers on the quality of LECG at the 1-Month Follow-Up visit (LECG vector with best combination of the highest R wave and most visible P wave).
The endpoints will be R wave amplitude and P wave visibility in different positions (meaning visible or not visible in both positions).
R wave changes and proportion of patients with stable P waves visibility at lying position versus other positions will be calculated by an independent reviewer.</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Factors Such as Device Rotation, Device Fixation, Device Side Facing the Skin, Position of Lead Loops in the Pocket, Use of Antiseptic Solution, Skin Type, Body Mass Index on the Quality of Leadless ECG.</title>
        <description>The following factors will be evaluated to investigate whether they influence the LECG quality:
device position (subcutaneous, submuscular, etc)
device rotation
device fixation
device side facing the skin
position of lead loops in the pocket
use of antibiotics in the pocket
skin type (loose, normal, firm)
body mass index (BMI)
The endpoints will be:
describe R wave amplitude values
describe proportion of patients with P wave visible on intrinsic LECG strips recorded at 1-Month FU.</description>
        <time_frame>30 to 120 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Overall Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>allergy to iodine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac decompensation / Global heart failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Phrenic nerve stimulation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>AV node / His ablation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>LV lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>LV lead threshold elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>multiviceral failure and cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>general fatigue sensation and feet formications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatocellular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pocket hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdnominal aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Slight deglobulisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>coronary sinus dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colonic ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Françoise Hidden-Lucet</name_or_title>
      <organization>Hôpital de la Pitié-Salpêtrière</organization>
      <phone>+33 1 42 16 00 00</phone>
      <email>francoise.hidden-lucet@psl.aphp.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
